Adelman Robert J 4
4 · Metacrine, Inc. · Filed Sep 22, 2020
Insider Transaction Report
Form 4
Metacrine, Inc.MTCR
Adelman Robert J
Director10% Owner
Transactions
- Conversion
Series A Convertible Preferred Stock
2020-09-18−1,960,784→ 0 total→ Common Stock (1,960,784 underlying) - Conversion
Common Stock
2020-09-18+2,829,123→ 3,059,123 total - Purchase
Common Stock
2020-09-18$13.00/sh+230,000$2,990,000→ 230,000 total - Conversion
Series B Convertible Preferred Stock
2020-09-18−472,250→ 0 total→ Common Stock (472,250 underlying) - Conversion
Series C Convertible Preferred Stock
2020-09-18−396,089→ 0 total→ Common Stock (396,089 underlying)
Footnotes (2)
- [F1]Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- [F2]The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.